Fig. 3From: A multicenter, double-blind, randomized, parallel-group, placebo-controlled study to evaluate the efficacy and safety of camostat mesilate in patients with COVID-19 (CANDLE study)Change in SARS-CoV-2 viral load over time. Values are mean ± standard deviationBack to article page